Skip to main content
. Author manuscript; available in PMC: 2024 Aug 21.
Published in final edited form as: Obstet Gynecol. 2024 Apr 17;143(6):718–729. doi: 10.1097/AOG.0000000000005586

Table 1.

Distribution of Demographic and Clinical Characteristics by Syphilis Surveillance Stage and Treatment Status, SET-NET (Surveillance for Emerging Threats to Pregnant People and Infants Network), Six States, 2018–2021

Not Treated or Inadequately Treated(n=621, 42.1%)
Characteristic Total (N=1,476) P/S/E (n=244)* LL/U (n=377) Total (n=621)

Urbanicity#
 Medium–large metropolitan (250,000 or more) 1,297 (88.0) 222 (91.7) 339 (89.9) 561 (90.6)
 Rural–small metropolitan (249,999 or fewer) 177 (12.0) 20 (8.3) 38 (10.1) 58 (9.4)
 Missing 2 (0.1) 2 (0.8) 0 (0.0) 2 (0.3)
Age at first diagnosis (y) 27 (23–31) 27 (22–31) 28 (24–33) 28 (23–32)
 24 or younger 574 (39.4) 90 (37.8) 114 (30.7) 204 (33.5)
 25–29 434 (29.8) 74 (31.1) 111 (29.9) 185 (30.4)
 30–34 289 (19.8) 45 (18.9) 85 (22.9) 130 (21.3)
 35 or older 160 (11.0) 29 (12.2) 61 (16.4) 90 (14.8)
 Missing 19 (1.3) 6 (2.5) 6 (1.6) 12 (1.9)
Race and ethnicity**
 American Indian, American Native, Native Hawaiian, Pacific Islander 78 (5.4) 14 (5.8) 22 (5.9) 36 (5.9)
 Asian 30 (2.1) 5 (2.1) 4 (1.1) 9 (1.5)
 Black, non-Hispanic 486 (33.8) 81 (33.8) 102 (27.3) 183 (29.8)
 Hispanic or Latinx 530 (36.9) 83 (34.6) 144 (38.5) 227 (37.0)
 Multiple or other unspecified 14 (1.0) 3 (1.3) 6 (1.6) 9 (1.5)
 White, non-Hispanic 298 (20.8) 54 (22.5) 96 (25.7) 150 (24.4)
 Missing 40 (2.7) 4 (1.6) 3 (0.8) 7 (1.1)
Health insurance at delivery
 Private 174 (15.0) 25 (14.3) 25 (8.6) 50 (10.8)
 Public 897 (77.2) 133 (76.0) 230 (79.3) 363 (78.1)
 Other, none, self-pay 91 (7.8) 17 (9.7) 35 (12.1) 52 (11.2)
 Missing 314 (21.3) 69 (28.3) 87 (23.1) 156 (25.1)
History of incarceration††
 Yes 91 (8.5) 15 (8.6) 33 (13.0) 48 (11.2)
 No 984 (91.5) 159 (91.4) 220 (87.0) 379 (88.8)
 Missing 401 (27.2) 70 (28.7) 124 (32.9) 194 (31.2)
History of homelessness††
 Yes 126 (11.7) 31 (18.7) 53 (20.2) 84 (19.6)
 No 946 (88.2) 135 (81.3) 209 (79.8) 344 (80.4)
 Missing 404 (27.4) 78 (32.0) 115 (30.5) 193 (31.1)
No. of prenatal care visits 8 (3–12) 6 (2–10) 2 (0–8) 4 (0–9)
Receipt of prenatal care
 Timely (at least 30 d before pregnancy outcome) 1,143 (82.2) 169 (74.1) 198 (56.4) 367 (63.4)
 Nontimely (less than 30 d before pregnancy outcome) 71 (5.1) 21 (9.2) 36 (10.3) 57 (9.8)
 No prenatal care 177 (12.7) 38 (16.7) 117 (33.3) 155 (26.8)
 Missing 86 (5.8) 16 (6.6) 26 (6.9) 42 (6.8)
MOUD receipt‡‡
 Yes 79 (5.5) 17 (7.6) 33 (9.3) 50 (8.6)
 No 1,345 (94.5) 208 (92.4) 321 (90.7) 529 (91.4)
 Missing 52 (3.5) 19 (7.8) 23 (6.1) 42 (6.8)
Any substance use§§
 Yes 279 (19.6) 55 (24.4) 137 (38.7) 192 (33.2)
 No 1,145 (80.4) 170 (75.6) 217 (61.3) 387 (66.8)
 Missing 52 (3.5) 19 (7.8) 23 (6.1) 42 (6.8)
Gestational age at pregnancy outcome (wk)
 Less than 35 222 (15.0) 53 (21.7) 114 (30.2) 167 (26.9)
 35 or more 1,254 (85.0) 191 (78.3) 263 (69.8) 454 (73.1)
 Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Adequately Treated (n=855, 57.9%)
Characteristic P/S/E (n=358) LL/U (n=497)§ Total (n=855) RR (95% CI) P

Urbanicity# .008
 Medium–large metropolitan (250,000 or more) 323 (90.2) 413 (83.1) 736 (86.1) 1.00 (ref)
 Rural–small metropolitan (249,999 or fewer) 35 (9.8) 84 (16.9) 119 (13.9) 0.76 (0.61–0.94)
 Missing 0 (0.0) 0 (0.0) 0 (0.0)
Age at first diagnosis (y) 26 (22–30) 26 (23–31) 26 (23–31) <.001
 24 or younger 156 (43.8) 214 (43.5) 370 (43.6) 1.00 (ref)
 25–29 107 (30.1) 142 (28.9) 249 (29.4) 1.20 (1.03–1.40)
 30–34 65 (18.3) 94 (19.1) 159 (18.8) 1.27 (1.07–1.50)
 35 or older 28 (7.9) 42 (8.5) 70 (8.3) 1.58 (1.33–1.89)
 Missing 2 (0.6) 5 (1.0) 7 (0.8)
Race and ethnicity** .004
 American Indian, American Native, Native Hawaiian, Pacific Islander 18 (5.2) 24 (5.0) 42 (5.1) 0.92 (0.70–1.20)
 Asian 5 (1.4) 16 (3.4) 21 (2.6) 0.60 (0.34–1.04)
 Black, non-Hispanic 135 (39.1) 168 (35.2) 303 (36.9) 0.75 (0.64–0.88)
 Hispanic or Latinx 125 (36.2) 178 (37.3) 303 (36.9) 0.85 (0.73–0.99)
 Multiple or other unspecified 2 (0.6) 3 (0.6) 5 (0.6) 1.28 (0.85–1.92)
 White, non-Hispanic 60 (17.4) 88 (18.4) 148 (18.0) 1.00 (ref)
 Missing 13 (3.6) 20 (4.0) 33 (3.9)
Health insurance at delivery <.001
 Private 45 (15.7) 79 (19.3) 124 (17.8) 1.00 (ref)
 Public 227 (79.1) 307 (74.9) 534 (76.6) 1.41 (1.10–1.80)
 Other, none, self-pay 15 (5.2) 24 (5.9) 39 (5.6) 1.99 (1.48–2.67)
 Missing 71 (19.8) 87 (17.5) 158 (18.5)
History of incarceration†† .008
 Yes 13 (4.9) 30 (7.8) 43 (6.6) 1.37 (1.11–1.69)
 No 250 (95.1) 355 (92.2) 605 (93.4) 1.00 (ref)
 Missing 95 (26.5) 112 (22.5) 207 (24.2)
History of homelessness†† <.001
 Yes 23 (8.7) 19 (5.0) 42 (6.5) 1.83 (1.58–2.13)
 No 241 (91.3) 361 (95.0) 602 (93.5) 1.00 (ref)
 Missing 94 (26.3) 117 (23.5) 211 (24.7)
No. of prenatal care visits 9 (6–12) 10 (7–12) 10 (6–12)
Receipt of prenatal care <.001
 Timely (at least 30 d before pregnancy outcome) 328 (95.3) 448 (95.7) 776 (95.6) 1.00 (ref)
 Nontimely (less than 30 d before pregnancy outcome) 5 (1.5) 9 (1.9) 14 (1.7) 2.50 (2.17–2.88)
 No prenatal care 11 (3.2) 11 (2.4) 22 (2.7) 2.73 (2.47–3.02)
 Missing 14 (3.9) 29 (5.8) 43 (5.0)
MOUD receipt‡‡ <.001
 Yes 16 (4.5) 13 (2.6) 29 (3.4) 1.61 (1.34–1.93)
 No 338 (95.5) 478 (97.4) 816 (96.6) 1.00 (ref)
 Missing 4 (1.1) 6 (1.2) 10 (1.2)
Any substance use§§ <.001
 Yes 42 (11.9) 45 (9.2) 87 (10.3) 2.04 (1.82–2.28)
 No 312 (88.1) 446 (90.8) 758 (89.7) 1.00 (ref)
 Missing 4 (1.1) 6 (1.2) 10 (1.2)
Gestational age at pregnancy outcome (wk) <.001
 Less than 35 32 (8.9) 23 (4.6) 55 (6.4) 2.08 (1.87–2.31)
 35 or more 326 (91.1) 474 (95.4) 800 (93.6) 1.00 (ref)
 Missing 0 (0.0) 0 (0.0) 0 (0.0)

P/S/E/, primary, secondary, or early latent; LL/U, late latent or unknown; RR, risk ratio; ref, reference; MOUD, medications for opioid use disorder.

Data are n (%) or median (interquartile range) unless otherwise specified.

*

Not treated or inadequately treated, inclusive of treatment other than penicillin or initial dose given less than 30 days before pregnancy outcome.

Not treated or inadequately treated, inclusive of treatment other than penicillin, initial dose given less than 30 days before pregnancy outcome, fewer than three doses given, or doses given outside of the recommended window (more than 9 days apart or less than 5 days apart).

Adequately treated with at least one dose of penicillin during pregnancy, with the dose administered at least 30 days before pregnancy outcome.

§

Adequately treated with at least three doses of penicillin, spaced 5–9 days apart, with the first dose administered at least 30 days before pregnancy outcome and the final dose occurring during pregnancy.

Combined across syphilis stages, excluding missing cases. Risk ratio describes the risk of inadequate or no syphilis treatment in each category vs the risk of inadequate syphilis treatment in the referent category.

P values from overall x2 tests of association or Fisher exact test of the null hypotheses that the distribution of the demographic or clinical characteristic are similar across the treatment categories (inadequate or no syphilis treatment vs adequate treatment).

#

The National Center for Health Statistics Urban-Rural Classification Scheme for Counties was used to categorize urbanicity as follows: medium–large metropolitan (population of 250,000 or greater) and rural–small metropolitan (population 249,000 or fewer).24

**

Race and ethnicity is top-coded in the following hierarchy: 1) Native Hawaiian/Pacific Islander, 2) American Indian/Alaska Native, 3) Asian, 4) Hispanic ethnicity, 5) multiple non-Hispanic races. “Other” race category was a response option in SET-NET (Surveillance for Emerging Threats to Pregnant People and Infants Network) for people whose race was not Native Hawaiian, Pacific Islander, American Indian, Alaska Native, Asian, Black or African American, or White.

††

Within the 12 months preceding case report or positive test results or during this pregnancy.

‡‡

The pregnant person received MOUD during this pregnancy.

§§

Defined as illicit use of opioids (eg, prescription opioids not taken as prescribed, fentanyl, or heroin) and other illicit, nonprescription substances (eg, cocaine, methamphetamines, inhalants, ecstasy, or hallucinogens, such as LSD or PCP) during this pregnancy.

Missing data were excluded from the denominators for calculating percentages.